A nurse holds a one-dose vial and a syringe prepared for the measles, mumps, and rubella vaccine made by Merck at the Utah County Health Department on April 29, 2019 in Provo, Utah.
George Frey | fake images
The deadly coronavirus worsened rapidly this month, shaking financial markets as investors fled risky assets amid concerns that the outbreak would disrupt the global economy. Meanwhile, several biotechnology companies have intensified vaccine or drug programs to combat the disease, which has caused investors to raise their shares amid the market downturn.
Merchants hope that their initiatives to develop the treatment and prevention of coronavirus can take shape at some point. Vir Biotechnology increased 111% in the last month, while Novavax gained 91% during the same period.
“At least a dozen companies have formally or informally announced vaccine or drug development initiatives to address” the virus, Needham analyst Alan Carr said in a note. “It seems that at least a few programs will have passed clinical trials in a few months.”
These programs include drugs already approved for other viral infections, unapproved drugs initially developed for other viruses, new monoclonal antibodies, new vaccines, the analyst said.
Inovio Pharmaceuticals shot up 37% in January, as it said it is in the process of developing a vaccine against the new deadly virus.
But analysts warned that any commercial Inovio treatment could be years away. Buyers in these actions should be careful, since that could be the problem with any of these names in the midst of unbridled speculation.
Morgan Stanley is optimistic about Moderna, who recently indicated that he is working on a possible coronavirus vaccine.
“Moderna has a potential benefit over traditional vaccine manufacturers in that once it has the sequences that encode the most immunogenic part of the surface proteins of the virus, or antigens, management can quickly become a candidate for clinical development. “said bank analyst Matthew Harrison. on a note
The analyst also has high hopes for Regeneron, saying his detection technology could be used to potentially produce therapeutic antibodies against the virus.
“During the Ebola outbreak, Regeneron was able to move from development to the validation of his therapeutic candidate in 6 months,” Harrison said.
– CNBC’s contributed to this report